These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 18825420

  • 1. Efficacy and safety of lisinopril for mild childhood IgA nephropathy: a pilot study.
    Nakanishi K, Iijima K, Ishikura K, Hataya H, Awazu M, Sako M, Honda M, Yoshikawa N, Japanese Pediatric IgA Nephropathy Treatment Study Group.
    Pediatr Nephrol; 2009 Apr; 24(4):845-9. PubMed ID: 18825420
    [Abstract] [Full Text] [Related]

  • 2. Lisinopril versus lisinopril and losartan for mild childhood IgA nephropathy: a randomized controlled trial (JSKDC01 study).
    Shima Y, Nakanishi K, Sako M, Saito-Oba M, Hamasaki Y, Hataya H, Honda M, Kamei K, Ishikura K, Ito S, Kaito H, Tanaka R, Nozu K, Nakamura H, Ohashi Y, Iijima K, Yoshikawa N, Japanese Study Group of Kidney Disease in Children (JSKDC).
    Pediatr Nephrol; 2019 May; 34(5):837-846. PubMed ID: 30284023
    [Abstract] [Full Text] [Related]

  • 3. Effects of angiotensin-converting enzyme inhibitor, angiotensin II receptor antagonist and calcium antagonist on urinary podocytes in patients with IgA nephropathy.
    Nakamura T, Ushiyama C, Suzuki S, Hara M, Shimada N, Sekizuka K, Ebihara I, Koide H.
    Am J Nephrol; 2000 May; 20(5):373-9. PubMed ID: 11092994
    [Abstract] [Full Text] [Related]

  • 4. Combination therapy with or without warfarin and dipyridamole for severe childhood IgA nephropathy: an RCT.
    Shima Y, Nakanishi K, Kaku Y, Ishikura K, Hataya H, Matsuyama T, Honda M, Sako M, Nozu K, Tanaka R, Iijima K, Yoshikawa N, Japanese Pediatric IgA Nephropathy Treatment Study Group.
    Pediatr Nephrol; 2018 Nov; 33(11):2103-2112. PubMed ID: 29987456
    [Abstract] [Full Text] [Related]

  • 5. Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy.
    Hogg RJ, Bay RC, Jennette JC, Sibley R, Kumar S, Fervenza FC, Appel G, Cattran D, Fischer D, Hurley RM, Cerda J, Carter B, Jung B, Hernandez G, Gipson D, Wyatt RJ.
    Am J Kidney Dis; 2015 Nov; 66(5):783-91. PubMed ID: 26209543
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effects of lisinopril administration on blood bcl-2 concentrations in patients with immunoglobulin A nephropathy.
    Buemi M, Allegra A, Corica F, Ruello A, Aloisi C, Pettinato G, Giacobbe M, Romeo A, Frisina N.
    Clin Pharmacol Ther; 1999 Jun; 65(6):649-52. PubMed ID: 10391670
    [Abstract] [Full Text] [Related]

  • 9. Effect of increasing doses of lisinopril on proteinuria of normotensive patients with IgA nephropathy and normal renal function.
    Palla R, Panichi V, Finato V, Parrini M, Andreini B, Bianchi AM, Giovannini L, Migliori M, Bertelli AA.
    Int J Clin Pharmacol Res; 1994 Jun; 14(1):35-43. PubMed ID: 7927959
    [Abstract] [Full Text] [Related]

  • 10. Combination therapy with mizoribine for severe childhood IgA nephropathy: a pilot study.
    Yoshikawa N, Nakanishi K, Ishikura K, Hataya H, Iijima K, Honda M, Japanese Pediatric IgA Nephropathy Treatment Study Group.
    Pediatr Nephrol; 2008 May; 23(5):757-63. PubMed ID: 18224343
    [Abstract] [Full Text] [Related]

  • 11. Dual renin-angiotensin system blockade plus oral methylprednisone for the treatment of proteinuria in IgA nephropathy.
    Trimarchi H, Muryan A, Young P, Forrester M, Iotti A, Pereyra H, Lombi F, Seminario O, Alonso M, Iotti R.
    Medicina (B Aires); 2007 May; 67(5):445-50. PubMed ID: 18051227
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Treatment with low-dose angiotensin-converting enzyme inhibitor (ACEI) plus angiotensin II receptor blocker (ARB) in pediatric patients with IgA nephropathy.
    Yang Y, Ohta K, Shimizu M, Nakai A, Kasahara Y, Yachie A, Koizumi S.
    Clin Nephrol; 2005 Jul; 64(1):35-40. PubMed ID: 16047643
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Low-dose sirolimus combined with angiotensin-converting enzyme inhibitor and statin stabilizes renal function and reduces glomerular proliferation in poor prognosis IgA nephropathy.
    Cruzado JM, Poveda R, Ibernón M, Díaz M, Fulladosa X, Carrera M, Torras J, Bestard O, Navarro I, Ballarín J, Romero R, Grinyó JM.
    Nephrol Dial Transplant; 2011 Nov; 26(11):3596-602. PubMed ID: 21393611
    [Abstract] [Full Text] [Related]

  • 17. Predictors of Progression in IgA Nephropathy in Childhood.
    Mizerska-Wasiak M, Małdyk J, Turczyn A, Cichoń-Kawa K, Rybi-Szumińska A, Wasilewska A, Bieniaś B, Zajączkowska M, Miklaszewska M, Pietrzyk J, Demkow U, Roszkowska-Blaim M, Pańczyk-Tomaszewska M.
    Adv Exp Med Biol; 2017 Nov; 955():65-73. PubMed ID: 27718216
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Disappearance of glomerular IgA deposits in childhood IgA nephropathy showing diffuse mesangial proliferation after 2 years of combination/prednisolone therapy.
    Shima Y, Nakanishi K, Kamei K, Togawa H, Nozu K, Tanaka R, Sasaki S, Iijima K, Yoshikawa N.
    Nephrol Dial Transplant; 2011 Jan; 26(1):163-9. PubMed ID: 20601366
    [Abstract] [Full Text] [Related]

  • 20. Fractional urinary excretion of IgG is the most powerful predictor of renoprotection by ACE inhibitors in IgA nephropathy.
    Bazzi C, Rizza V, Paparella M, Casellato D, Napodano P, Olivieri G, D'Amico G.
    J Nephrol; 2009 Jan; 22(3):387-96. PubMed ID: 19557716
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.